Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- ...
Silo Pharma (SILO) entered into a non-binding Letter of Intent with Allucent to provide clinical research services for two planned Phase 1 studies ...
By improving BP control and treatment adherence, use of fixed-dose combination therapies is expected to drive down CV events ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback